GHK-Cu news and clinical trials

Researchers evaluated the stability of liposome-encapsulated GHK-Cu in cosmetic formulations using capillary electrophoresis coupled with mass spectrometry. The study demonstrates that liposomes can successfully encapsulate GHK-Cu, potentially enhancing transdermal delivery.

A systematic review of GHK-Cu literature through August 12, 2026, found that while preclinical data supports its role in tissue repair, clinical evidence remains limited. The review highlights that many delivery studies fail to resolve critical factors like molar copper occupancy.

A systematic review of GHK-Cu literature published between 2005 and 2026 identified a lack of adequately powered human trials using microneedle delivery. Researchers found extensive preclinical evidence for tissue regeneration but noted that further clinical testing is required.

Researchers developed biodegradable polymer STAR particles-using materials like cellulose acetate and polylactic acid-to painlessly puncture skin and deliver drugs. Tests showed these particles increased intradermal drug delivery of agents like copper tripeptide-1 by up to 37-fold.

A narrative review summarized the current evidence on regenerative peptides used for chronic pain management. The authors concluded that clinical evidence in humans remains limited and most of these therapies currently lack FDA approval.

A systematic review of 20 studies on GHK-Cu in aesthetic medicine indicates it enhances extracellular matrix synthesis and reduces inflammation in preclinical models. Clinical data, though limited, suggests improvements in wrinkle depth and patient satisfaction after procedures.

Scientists designed an injectable hydrogel containing tea exosomes, glucose oxidase, and GHK-Cu for diabetic wound healing. The material accelerates wound repair by lowering glucose levels, reducing hypoxia, and promoting antibacterial activity.

A scoping review concluded that claims regarding peptide supplements for musculoskeletal recovery remain unsubstantiated by current human trials. Authors warned of potential risks including cardiovascular complications.

A study found that combining a ferment extract from Thermus thermophilus and Bacillus subtilis with GHK-Cu outperformed the individual ingredients in skin tests. This combination reduced inflammatory cytokines and improved skin barrier function in human skin explants and clinical tests.

Researchers developed a complex of Torilis japonica extract and GHK-Cu, finding that an optimized 6:4 ratio synergistically suppressed Th2 cytokines and improved keratinocyte migration. This formulation warrants further investigation for atopic dermatitis management.

LifeWave, Inc. registered a clinical trial to evaluate the effects of the X39 patch on circulating blood levels of GHK and GHK-Cu in 100 healthy adults. The study compares the patch to a placebo over an 8-day period.

Researchers developed a hydrogel loaded with glucose oxidase and GHK-Cu to treat infected diabetic wounds. The system simultaneously lowers local glucose levels and releases oxygen to alleviate hypoxia, promoting tissue repair and antibacterial activity.

Researchers published a study in Biomaterials advances describing the development of poly(γ-benzyl-L-glutamate) microspheres grafted with GHK-Cu. These scaffolds enhanced bone marrow mesenchymal stem cell mineralization and stimulated angiogenesis, showing potential for bone defect repair.

A study of aged mice found that intranasal GHK-Cu (15 mg/kg) improved hippocampal-dependent learning and suppressed growth and metabolic signaling, while intraperitoneal dosing (15 mg/kg) activated stress-response and repair pathways with less sustained cognitive impact.

Researchers investigated a combination therapy using Copper Tripeptide-1, ethyl ferulate, and cedrol on UV-damaged human skin biopsies. They found that this multi-target approach effectively mitigated elastic fiber disruption and improved fiber architecture.

A study using Caenorhabditis elegans showed that GHK-Cu significantly extended lifespan and improved aging-related phenotypes. The peptide delayed aging by preserving mitochondrial function and activating the DAF-16 and SKN-1 pathways.

Scientists created an injectable hydrogel using carboxymethyl chitosan and GHK-Cu to treat radiation-induced skin injury. The hydrogel releases GHK-Cu to promote tissue repair and collagen deposition while scavenging reactive oxygen species to reduce oxidative stress.

Researchers revealed the laccase-like property of GHK-Cu, which demonstrated a V max of 1.735 × 10 -4 mM·s -1 and a K m of 0.061 mM. This catalytic efficiency allowed for the development of a sensor capable of rapid colorimetric detection of phenolic compounds like epinephrine.

New review in Frontiers in aging: Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

Researchers tested GHK-Cu in a zebrafish larvae model and found it attenuated acute inflammation by suppressing pro-inflammatory cytokines like tnf-a, il-1β, and il6. The peptide also mitigated oxidative stress and downregulated the JAK1 pathway.

Researchers published a review of approved and unapproved peptide therapies used in sports medicine. They found that while unapproved peptides often show potential for tissue repair in animal models, human safety data remain scarce and carry a risk of serious harm.

Hudson Biotech is recruiting for a Phase 2 trial to test if a topical GHK-Cu gel can accelerate the healing of standardized punch-biopsy wounds in 60 healthy adults. The study compares the gel to a vehicle gel over 3 weeks.

A review in the journal Antibiotics surveys emerging multifunctional strategies for wound management, including the use of bioactive peptides like GHK-Cu and antimicrobial peptides alongside scaffolds and real-time monitoring technologies.

A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.

A narrative review evaluated evidence for injectable peptide therapy in orthopaedic and sports medicine. The authors concluded that current clinical data remain limited or unvalidated for peptides like BPC 157 and others, necessitating further research before clinical use.

Researchers validated a Golgi-targeted copper delivery system using GHK-Cu and ATOX1-encoding nanoparticles to enhance fascia regeneration. In rabbit models, this strategy increased LOX activity to 1.78 times that of the control group and improved extracellular matrix reconstruction.